Urolithin A Flunked Its Trial — Then Delivered a Surprise

Picture this: you take a trendy supplement for four weeks, get hooked up to ultrasound machines and brain scanners, and the headline result is… a miss. That is what happened in a new randomized trial of urolithin A, published this week. But before you file it under “another supplement fail,” look closer — the same study found something in the brain that has researchers raising their eyebrows.

The plan: fix tired arteries by rebooting the batteries

Here is why researchers bothered. Nearly half of middle-aged U.S. adults live with obesity, which is linked to stiff, underperforming blood vessels. One suspect: worn-out mitochondria — the tiny power plants inside your cells. When damaged ones are not cleared away, oxidative stress builds and blood vessels do not relax the way they should.

Enter urolithin A. Certain gut bacteria make it when you eat ellagitannin-rich foods — think pomegranate, berries, and walnuts. In lab studies, it flips on mitophagy: your cells’ recycling program for damaged mitochondria. Animal studies suggested this could help blood vessels, so the Oklahoma team ran the first human trial asking directly: does four weeks of urolithin A improve endothelial function in middle-aged adults with obesity?

The design was clean: double-blind and placebo-controlled — neither the participants nor the researchers knew who got what.

What actually happened: a clean miss — and a weird win

The main result is simple: the arteries did not budge. The primary measure was brachial artery flow-mediated dilation, or FMD — how much an arm artery widens after blood flow is briefly cut off and released. After four weeks, both groups were basically identical (urolithin A: +1.3%, placebo: +0.3% — statistical noise). Backup measures in the hand and fingers agreed: no meaningful difference.

So the trial failed its main question. Full stop. In a world of supplement hype, an honest “nope” is worth something.

Then came the brain part. Participants also did memory challenges (an N-back task — remembering letters shown several steps back) while a non-invasive light-based scanner measured brain blood flow. The urolithin A group showed a significantly larger increase in task-evoked blood-flow responses than placebo. In plain terms: when the brain worked hard, its blood supply responded more strongly.

The honest catch: participants did not perform better on the memory tasks. More blood flow during effort, same scores. A brain-blood-flow finding, not a memory finding. The researchers’ verdict: safe and feasible, but the brain effect “merits further investigation” — scientist-speak for “interesting, now somebody run a bigger, longer study.”

Why this brain hint is only a hint

Three reasons to keep excitement on a leash. First, 50 people and four weeks is a proof-of-concept, not a definitive answer. Second, the brain finding was a secondary outcome — measure enough things and some look good by chance. Third, better blood flow during thinking is not better thinking. Until a longer trial shows real cognitive benefits, this stays in the “fascinating, unproven” file.

Still, it is a genuinely interesting twist for an ingredient mostly studied for muscles. A 2022 randomized trial found about 12% better muscle strength and improved aerobic endurance after four months — though it was company-funded, and it missed its own primary endpoint too. Nobody expected the brain to show up. That is the kind of surprise that makes follow-up research worth doing.

What is urolithin A and how is it supposed to work?

Urolithin A is not a vitamin or mineral — it is a postbiotic, made by your gut bacteria when they digest ellagitannins, the bitter polyphenols in pomegranate, berries, and walnuts.

The catch: only a minority of people seem to have the right gut machinery, and production tends to be lower in obesity. That is the whole pitch for taking it directly: skip the gut lottery and get the compound itself.

The proposed mechanism is mitophagy — your cells’ quality-control system for mitochondria. Damaged ones get recycled so healthy ones can take over. An appealing story for aging muscles and blood vessels; whether it holds up in humans is what trials like this one are testing.

What are the side effects of urolithin A?

The human safety data look reassuring — but thin. A 2019 first-in-human trial in healthy older adults reported a favourable safety profile, and this new trial described urolithin A as well tolerated, with no serious safety signals over four weeks.

What is missing matters too. No solid data on pregnancy or breastfeeding, and very little on drug interactions. The trials are small and short — weeks to a few months — which cannot spot rare or long-term issues. If you are pregnant, nursing, taking prescription drugs, or managing a liver condition, talk to your doctor or pharmacist first.

How much urolithin A should you take?

There is no official recommended intake — research is still figuring it out. Human trials cluster around two doses: 500 mg and 1,000 mg per day. The 2019 safety trial tested both over four weeks; the 2022 muscle trial used both for four months; this trial used 1,000 mg a day.

More is not better. Nobody has tested megadoses in humans, and taking a supplement for months at an unstudied dose is a gamble. If research settles on a dose, it will most likely be the 500–1,000 mg range trials actually used.

What should you look for on the label?

If you are shopping in Canada, check for the 8-digit Natural Product Number (NPN) on the label first. That number means Health Canada has licensed the product and reviewed it for safety, quality, and label claims. No NPN, no licence — put it back.

Beyond that, look for the exact urolithin A amount per serving in milligrams (research used 500–1,000 mg), third-party testing, and a short, clear ingredient list. Skip anything that hides the dose in a “proprietary blend” — if a company will not say how much active ingredient is in the capsule, move on. A single-ingredient product is easier to judge than a kitchen-sink “longevity” formula.

One last reality check: this is one small study. Urolithin A is an interesting research compound with early muscle signals and now a brain-blood-flow hint — not a proven brain booster, artery fixer, or fountain of youth. The science is moving, but it has not arrived.

This article reports on recent health research and is for general information only — it isn’t medical advice and doesn’t replace your doctor, pharmacist, or another qualified professional. Study findings describe what researchers observed, not a promise of results, and nothing here claims any supplement can diagnose, treat, cure, or prevent a disease. These statements have not been evaluated by Health Canada. Check with a healthcare professional before starting any new supplement, especially if you’re pregnant, nursing, taking medication, or managing a health condition.